Specialty Oncology
-
Featured
Tracking Outcomes in Proton Therapy for Cancer
Massachusetts General Hospital clinician-researchers work to define which patients can benefit most from advanced proton therapy for cancer.
-
Featured
Overcoming Barriers to Lung Cancer Screening
Lung cancer screening is an extremely underused tool. Review the lung cancer screening guidelines with the American Lung Cancer Screening Initiative's founder, Chi-Fu Jeffrey Yang, MD, of Massachusetts General Hospital.
-
Revolutionizing Palliative Care Delivery and Access to Improve Outcomes for Patients and Caregivers
Research at Massachusetts General Hospital is shifting how integrated palliative and oncology care is delivered to support patients with cancer and caregivers.
-
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Ryan J. Sullivan, MD, Michael L. Dougan, MD, PhD, and colleagues have reported the first three cases of using a Janus kinase (JAK) inhibitor to treat hepatitis associated with immune checkpoint inhibitor therapy. All patients showed excellent response to tofacitinib, although their oncologic outcomes varied.
-
Three Things to Know About the Revamped Gordon Center for Medical Imaging
Matthias Nahrendorf, PhD, the recently appointed director of the Center, describes its new research emphasis and "extremely collaborative" mission.
-
"DrugMap" Expected to Accelerate Cancer Drug Discovery
Liron Bar-Peled, PhD, Michael Lawrence, PhD, and colleagues have developed "DrugMap," an atlas of cysteine ligandability compiled across 416 cancer cell lines that lays the groundwork for precision anti-cancer drugs to be systematically developed for additional classes of oncogenic drivers.
Mass General Cancer Center Contributors
-
Andrew T. Chan, MD, MPH
Daniel K. Podolsky Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
Post-Diagnosis Multivitamin Supplementation May Prolong Survival Among Patients With Nonmetastatic CRC
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
Program Co-Chair, Keith Flaherty, MD, Recaps Key Highlights From AACR 2024
-
Keyan Salari, MD, PhD
Director of Translational Research, Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Director, Prostate Cancer Genetics Program, Mass General Cancer Center, Assistant Professor of Surgery, Harvard Medical School
Recent Article
Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma
-
Marcela G. del Carmen, MD, MPH
President, Massachusetts General Physicians Organization, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Executive Vice President, Mass General Brigham
Recent Article
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Case Series: Intraventricular Infusion of Dual-targeting CAR T-Cells for Glioblastoma
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
